Investor SymposiumNovember 2015

MGC Pharmaceuticals

Company OverviewMGC Pharmaceuticals (MGC), is a medical and cosmetic cannabis company with licenses to grow, extract and sell Cannabis Sativa in Slovenia, inside the EU.

MGC holds unique genetics consisting of an exclusive strain of “Cannabis Sativa” which comprises of very low Tetrahydrocannabinol (THC) at below 0.3% and a very high Cannabidiol (CBD) content of above 10%.

MGC is currently developing its own product range of cosmetic and over-the-counter (OTC) medical products in partnership with its JV partner, Dr. M. Burstein.

MGC PharmaceuticalsCapitalising on “Israeli Medical Cannabis IP” – world leaders in the production and delivery of medical cannabis products

2

$2.7 million initial capital raising

completed

Some wolves, their habitat destroyed and overwhelmed by human pressures, turn to snorting quack...

4

Selected Pharmacologic Features of Cannabinoids Showing Antiseizure Effects in Preclinical Models.

Friedman D, Devinsky O. N Engl J Med 2015;373:1048-1058

MGC Pharma- Key Points Of Difference

7

Sources: Credit Suisse – Market Research, ArcView Group,

• Positioned in the rapidly growing medical cannabis market (worth US$2.7bn globally) and cosmetic market (estimated at US$270 b globally in 2014)

• Focused strategy to enter the Australian market following the favourable regulatory shift by the Federal Government

• Unique genetics from exclusive strain of Cannabis Sativa comprising very low THC levels (<0.32) and high CBD levels (>10%) - yielding higher amounts of CBD by 4x against existing hemp crops

• Fully Licensed Operation established in Slovenia to Grow, Extract and Import/Export into EU markets

• Highly experienced team with commercial success in the medical cannabis industry in Israel - a world leader in the industry

• Multiple revenue streams, with significant uplift from full production capacity to be realized in 2017

• $60m off take agreement for MGC’s initial CBD production starting mid 2016• MGC cosmetic and OTC medical products – first sales and revenues end 2015

Wealth of industrial cannabis Sativa (Hemp) managing and extraction experience, he shares Mr. Segev’s vision of building a large scale European extraction facility and has the necessary skills to establish and run a successful growing operation and extraction facility. He has extensive commercial business contacts in the European industry.

Previously CEO of Israel’s second largest licensed Medical Cannabis company, Cann Pharmaceuticals. Led the company to fully commercialize from startup position . Founded MGC Pharmaceuticals to expand into the huge European market for cannabinoids in the cosmetic industry.

MC Industry Leaders- Expertise and Experience

8

Nativ SegevCo-Founder and

Managing Director

Roby ZomerCo-Founder, President &

CTO

A prominent practising cardiologist and host of weekly radio 2UE program: Healthy Living. He has his own medical practice and specialises in all aspects of echocardiography. Other area of expertise is in the field of preventative cardiology. He has published seven books on preventative health and regularly lectures both nationally and internationally.

Dr Ross WalkerNon-Executive Director and Head of Advisory

BoardJoins upon completion of

transaction

9

Business Model

10

Multiple revenue streams –

from CBD off-take agreements and

cosmetic and OTC medical products sales.

Opportunity to leverage growing and extraction expertise in the Australian Market.

MGC has a business model which closes the supply chain –demand exists for the end products and MGC is now working towards establishing the supply of the raw material.

• Development of Cannabis Strains in Slovenian Laboratory.

• Plantation and harvesting of crops in outdoor facility in Slovenia. Cultivation

• Crops to be processed on site at Slovenian facility and CBD extracted

• Targeting 60% purity CBD resin• MGC has the capability to process other crops on

site

Extraction

• Sell CBD Extract into: •Wholesale markets – other off-takes in pipeline•Off-take with Natura JV to utilise in cosmetic products.

Distribution & Sales

11

Medical Cannabis could be legally available in Australia as early as 2016

12

MGC Australian Strategy MGC to be first in line to exploit scalable commercial opportunities in

Australia for CBD based expertise and products

13

Appointment of Dr Ross Walker as Non-Executive Director and Head of Strategic Advisory Board.

Collaboration with University of Sydney Business School on research and commercial opportunities in Australia.

Leverage Dr Ross Walker’s significant contacts in Australia and potential for access to distribution channels for MGC’s CBD products.

Take advantage of tax incentives from new Federal Government innovation and research push.

Com

plet

eN

ext

Step

s

Global Market Opportunity – Medical Cannabis

14

• Cannabinoids are legal in 23 U.S states and the medical cannabis market is estimated to be worth USD$2.7 billion globally in 2014 and US$10 billion by 2019

• In Canada the market for medical cannabis is expected to grow significantly, from $144m in 2014

• Common diseases for which Cannabinoids have shown high levels of efficacy have combined sales of +US$300 million to date

Sources: ArcView Group, The HIA, Statista

15

Capital Structure

16

1. 100,000,000 Performance Shares upon MGC securing an off-take agreement to sell commercial quantities of CBD resin that contains a minimum purity of 50%, and achieving first revenues of at least 1m Euro within three years, as detailed in ASX announcement dated 18 May 2015.

Note- On completion of acquisition, MGC vendor securities will be escrowed pursuant to Ch 1&2 of the ASX Listing Rules

Ordinary Shares

Performance Shares

Unlisted Options Cash

Current issued capital 507,586,552 Nil 53,500,000 $2.0mShares to be issued to consultants and prospectus shares

3,846,700 Nil Nil Nil

Underwriting Options to be issued Nil Nil 20,000,000 Nil

MGC vendor consideration securities 200,000,000 100,000,000

1 Nil Nil

Total 711,433,252 100,000,0001 73,500,000 ~$2.0m

Cannabidiol (CBD) – Global PotentialScientific and clinical studies indicate that CBD could be effective in easing symptoms of a wide range of difficult-to-control conditions, including:

17

Nausea

Inflammatory Disorders

Anxiety and

Depression

Tumors and

Cancerous Cells1

Diabetes

Rheumatoid arthritis

Epilepsy

Schizophrenia

Chronic Pain 2

Multiple Sclerosis

Skin Conditions:

Psoriasis and Acne

1. CBD has demonstrated neuro-protective effects, and its anti-cancer potential is currently being explored at several academic research centers in the U.S. and other countries.

2. Impacts pathways in the body, which control pain and support the immune system, thereby delivering significant medicinal benefits in the treatment of chronic pain

18

CBD- Treatment of Epilepsy-Despite over 20 different anti-seizure drugs available, 30% of patients with epilepsy still experience seizures-A recent study of 137 patients with severe, refractory epilepsy on maximal standard anti-convulsant therapy, given a purified CBD extract, had a 54% reduction in seizure frequency

19

Clinical Trials, Case Series, and Case Reports on Cannabinoids in the Treatment of Epilepsy.

Friedman D, Devinsky O. N Engl J Med 2015;373:1048-1058

CBD- Treatment of Chronic Pain -7 % of Australians suffer some form of chronic pain-There are increasing issues with the over-prescription of narcotic analgesics & significant side effects of non steroidal anti-inflammatory drugs

-A number of studies are showing a significant reduction in pain & improvements in sleep parameters in a variety of CBD based products

21

CBD- Treatment of Cancer

3 Areas of Potential Benefit1) Chemotherapy induced

nausea2) Cancer pain3) Cancer growth & spread

22

CBD- Treatment of MS and Alzheimers

3 Areas of Potential Benefit1) Spasticity2) Neuropathic pain3) Central Nervous System inflammation

24

25

CONCLUSIONS1)MULTIPLE THERAPUETIC BENEFITS

FOR MEDICAL CANNABIS IN THE FORM OF CBD

2)AN EXTENSIVE RANGE OF SKIN CARE, COSMETIC & OTHER OTC PRODUCTS

3)EXCELLENT INVESTMENT OPPRTUNITIES

Disclaimer

29

This presentation has been prepared by Erin Resources Limited to be renamed MGC Pharmaceuticals Ltd (“Company”).  It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.Future mattersThis presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.US disclosureThis document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

Contact Information

30

Media EnquiriesAsher MosesDirectorMedia and Capital Partners+61 438 008 616Asher.moses@mcpartners.com.au ERIN soon to be MGC Pharmaceuticals Brett MitchellExecutive Chairman+61 8 9389 2000brett@mgcpharma.com.au